NL-OMON25545尚未招募不适用
CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Histologically confirmed stage IIIB and stage IV NSCLC KRAS positive tumors only. Tumor mutation analyzed by next generation sequencing for specific KRAS mutation.
- •2.The tumor tissue sample must be fresh, preferably fresh frozen, in addition to routine FFPE-tissue processing from the primary tumor, core needle biopsy, excisional or incisional biopsies are accepted. Fine needle biopsies and drainage of pleural effusions with cytospins are considered adequate for this biomarker study, but a KRAS mutation must be present and verified.
排除标准
- •1.Previous treatment with PD-1 or PD-L1 inhibitor.
- •2.Lung cancer previously treated for an ALK translocation, EGFR mutation or BRAF mutation.
研究者
相似试验
已完成
不适用
CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer, an exploratory studyNon-small cell lung cancer (NSCLC)10038666NL-OMON45880niversitair Medisch Centrum Groningen40
已完成
Unknown
INTENT_Circulating tumor cells as biomarkers for recurrence risk in thermoablatioC22.0Liver cell carcinomaDRKS00016808Klinikum der Universität München, Campus Großhadern100
已完成
不适用
tudy on Biomarkers Using Circulating Tumor Cells When Administering Osimertinib in Patients with EGFR Mutation-positive Lung CancerJPRN-UMIN000032055Toho University50
已完成
不适用
Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinomaC25Malignant neoplasm of pancreasDRKS00023929Allgemein- und Viszeralchirurgie Uniklinik Freiburg14
进行中（未招募）
不适用
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.Metastatic CancerCastration-resistant Prostate CancerCirculating Tumor CellsProstate CancerNCT03381326Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori104